Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date

References

• RappSRFeldmanSRExumMLFleischerABReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 Pt 140140710459113
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• HawkesJEChanTCKruegerJGPsoriasis pathogenesis and the development of novel targeted immune therapiesJ Allergy Clin Immunol2017140364565328887948
   PubMed Web of Science ®Google Scholar
• TorresTInhibidores selectivos de la IL-23: los recién llegados al tratamiento de la psoriasisActas Dermo-Sifiliográficas2018109867467630041866
   PubMed Web of Science ®Google Scholar
• TorresTSelective Interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumabDrugs201777141493150328770513
   PubMed Web of Science ®Google Scholar
• MachadoÁTorresTGuselkumab for the treatment of psoriasisBio-Drugs2018322119128
   Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• StroberBEBissonnetteRFiorentinoDComparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]J Am Acad Derma-tol2016745851861
   PubMed Web of Science ®Google Scholar
• KirkhamBWKavanaughAReichKInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisImmunology2014141213314223819583
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535627299809
   PubMed Web of Science ®Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291
   PubMed Web of Science ®Google Scholar
• PuigLBrodalumab: the first anti-IL-17 receptor agent for psoriasisDrugs Today201753528328650001
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis-results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• AbrahamCDulaiPSVermeireSSandbornWJLessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseasesGastroenterology2017152237438827780712
   PubMed Web of Science ®Google Scholar
• AminMDarjiKNoDJWuJJDjNJjWReview of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasisJ Eur Acad Dermatol Venereol201731101627163228667777
   PubMed Web of Science ®Google Scholar
• TorresTPuigLTreatment goals for psoriasis: Should PASI 90 become the standard of care?Actas Dermosifiliogr2015106315515725455503
   PubMed Web of Science ®Google Scholar
• SaunteDMMrowietzUPuigLZachariaeCCandida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical managementBr J Dermatol20171771476227580411
   PubMed Web of Science ®Google Scholar
• BlauveltASafety of secukinumab in the treatment of psoriasisExpert Opin Drug Saf201615101413142027545070
   PubMed Web of Science ®Google Scholar
• KruegerJGFerrisLKMenterAAnti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJ Allergy Clin Immunol2015136111612425769911
   PubMed Web of Science ®Google Scholar
• PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med2017376161551156028423301
   PubMed Web of Science ®Google Scholar
• ToussirotEThe IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseasesInflamm Allergy Drug Targets201211215916822280236
   PubMedGoogle Scholar
• GirolomoniGStrohalRPuigLThe role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasisJ Eur Acad Dermatol Venereol201731101616162628653490
   PubMed Web of Science ®Google Scholar
• GaffenSLJainRGargAVCuaDJThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingNat Rev Immunol201414958560025145755
   PubMed Web of Science ®Google Scholar
• FragoulisGESiebertSMcinnesIBTherapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseasesAnnu Rev Med201667133735326565676
   PubMed Web of Science ®Google Scholar
• ChiricozziASaracenoRChimentiMSGuttman-YasskyEKruegerJGRole of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?Expert Opin Ther Targets201418551352524568095
   PubMed Web of Science ®Google Scholar
• ChiricozziARomanelliPVolpeEBorsellinoGRomanelliMScanning the immunopathogenesis of psoriasisInt J Mol Sci2018191179
   PubMed Web of Science ®Google Scholar
• ChanTCHawkesJEKruegerJGInterleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatmentTher Adv Chronic Dis20189511111929796240
   PubMed Web of Science ®Google Scholar
• CingozOUstekinumabCOUstekinumabMAbs20091321622120069753
   PubMed Web of Science ®Google Scholar
• LevinAAGottliebABSpecific targeting of interleukin-23p19 as effective treatment for psoriasisJ Am Acad Dermatol201470355556124373779
   PubMed Web of Science ®Google Scholar
• KuligPMusiolSFreibergerSNIL-12 protects from psoriasiform skin inflammationNat Commun201671346627892456
   PubMed Web of Science ®Google Scholar
• van der FitsLMouritsSVoermanJSImiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axisJ Immunol200918295836584519380832
   PubMed Web of Science ®Google Scholar
• ChangHDRadbruchAThe pro- and anti-inflammatory potential of interleukin-12Ann N Y Acad Sci2007110930404617785289
   PubMed Web of Science ®Google Scholar
• HamzaTBarnettJBLiBInterleukin 12 a key immunoregulatory cytokine in infection applicationsInt J Mol Sci201011378980620479986
   PubMed Web of Science ®Google Scholar
• LuXImpact of IL-12 in CancerCurr Cancer Drug Targets201717868269728460617
   PubMed Web of Science ®Google Scholar
• GatelyMKRenzettiLMMagramJThe interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responsesAnnu Rev Immunol19981614955219597139
   PubMed Web of Science ®Google Scholar
• SuleimanAAKhatriAMinochaMOthmanAAPopulation phar-macokinetics of the Interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s disease: analyses of Phase I and II trialsClin Pharmacokinet201857897798829076110
   PubMed Web of Science ®Google Scholar
• GordonKBStroberBLebwohlMEfficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsLancet20183921014865066130097359
   PubMed Web of Science ®Google Scholar
• ReichKGooderhamMThaçiDCrowleyJRyanCKruegerJEfficacy and Safety of Risankizumab Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Phase 3 IMMvent TrialParis27th EADV Congress2018
   Google Scholar
• StroberBLambertJGuYZhanTThompsonEValdecantosWMAImpact of Prior Treatment History on Efficacy of Risankizumab Compared with Placebo in Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analyses from Three Phase 3 TrialsParis27th EADV Congress2018
   Google Scholar
• KimJKruegerJGHighly effective new treatments for psoriasis target the IL-23/Type 17 T cell autoimmune axisAnnu Rev Med201768125526927686018
   PubMed Web of Science ®Google Scholar
• HawkesJEYanBYChanTCKruegerJGDiscovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasisJ Immunol201820161605161330181299
   PubMed Web of Science ®Google Scholar
• MarkhamAGuselkumab: first global approvalDrugs201777131487149228819723
   PubMed Web of Science ®Google Scholar
• SignorovitchJEBettsKAYanYSComparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm responseBr J Dermatol2015172250451225288183
   PubMed Web of Science ®Google Scholar
• BlauveltAReichKTsaiTFSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR studyJ Am Acad Dermatol2017761606927663079
   PubMed Web of Science ®Google Scholar
• ReichKPinterALacourJPComparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyBr J Dermatol201717741014102328542874
   PubMed Web of Science ®Google Scholar
• SofenHSmithSMathesonRTGuselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisJ Allergy Clin Immunol201413341032104024679469
   PubMed Web of Science ®Google Scholar
• JägerAKuchrooVKEffectorKVKEffector and regulatory T-cell subsets in autoimmunity and tissue inflammationScand J Immunol201072317318420696013
   PubMed Web of Science ®Google Scholar
• GaglianiNAmezcua VeselyMCIsepponATh17 cells transdifferentiate into regulatory T cells during resolution of inflammationNature2015523755922122525924064
   PubMed Web of Science ®Google Scholar
• ClineAFeldmanSRRisankizumab for psoriasisLancet20183921014861661730097360
   PubMed Web of Science ®Google Scholar
• PuigLThe role of IL 23 in the treatment of psoriasisExpert Rev Clin Immunol201713652553428165883
   PubMed Web of Science ®Google Scholar
• PappKGottliebABNaldiLSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)J Drugs Dermatol201514770671426151787
   PubMed Web of Science ®Google Scholar
• PappKAGriffithsCEGordonKLong-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBr J Dermatol2013168484485423301632
   PubMed Web of Science ®Google Scholar
• FeaganBGPanésJFerranteMRisankizumab in patients with moderate to severe Crohn’s disease: an open-label extension studyLancet Gastroenterol Hepatol2018
   Web of Science ®Google Scholar
• FeaganBGSandbornWJD’HaensGInduction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 studyLancet2017389100801699170928411872
   PubMed Web of Science ®Google Scholar
• VisvanathanSBaumPSalasASelective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and Ileum of patients with active Crohn’s disease: results from a randomised Phase II biopsy sub-studyJ Crohn’s Colitis2018380
   Google Scholar